TY - JOUR
T1 - Associations of uric acid with the risk of cardiovascular disease and all-cause mortality among individuals with chronic kidney disease
T2 - the Kailuan Study
AU - Li, Na
AU - Cui, Liufu
AU - Shu, Rong
AU - Song, Haicheng
AU - Wang, Jierui
AU - Chen, Shuohua
AU - Han, Yixuan
AU - Yu, Ping
AU - Yuan, Wei
AU - Wang, Jian
AU - Gao, Huanqing
AU - Huang, Tao
AU - Gao, Xiang
AU - Wu, Shouling
AU - Geng, Tingting
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.
PY - 2024/11/1
Y1 - 2024/11/1
N2 - Aims: The relationship between uric acid (UA) concentrations and the risk of cardiovascular disease (CVD), especially for subtypes of CVD among individuals with chronic kidney disease (CKD), is not well understood. This study aimed to investigate whether UA concentration was associated with subtypes of CVD and all-cause mortality among individuals with CKD. Methods and results: A total of 27 707 individuals with CKD, free of CVD at recruitment from the Kailuan Study, were included. Cox proportional hazards regression models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs). Over a median follow-up of 11-12 years, we documented 674 myocardial infarctions, 1197 heart failures, 2406 strokes, and 5676 total deaths. Among participants with CKD, compared with those in the lowest tertile of UA, the HRs (95% CIs) of participants in the highest UA tertile were 1.38 (1.13-1.67) for myocardial infarction, 1.60 (1.38-1.85) for heart failure, 1.01 (0.91-1.12) for stroke, and 1.29 (1.21-1.38) for all-cause mortality. Subgroup analyses showed that the associations between UA and heart failure and all-cause mortality were stronger in individuals with estimated glomerular filtration rate <45 mL/min/1.73 m2 compared to their counterparts (Pinteraction < 0.05). Additionally, the association between UA and all-cause mortality was stronger among individuals without diabetes than those with diabetes (Pinteraction < 0.05). Conclusion: In individuals with CKD, a higher concentration of UA was associated with a higher risk of myocardial infarction, heart failure, and all-cause mortality, following a dose-response relationship. Our data underscore the importance of UA screening among individuals with CKD for CVD and premature death prevention.
AB - Aims: The relationship between uric acid (UA) concentrations and the risk of cardiovascular disease (CVD), especially for subtypes of CVD among individuals with chronic kidney disease (CKD), is not well understood. This study aimed to investigate whether UA concentration was associated with subtypes of CVD and all-cause mortality among individuals with CKD. Methods and results: A total of 27 707 individuals with CKD, free of CVD at recruitment from the Kailuan Study, were included. Cox proportional hazards regression models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs). Over a median follow-up of 11-12 years, we documented 674 myocardial infarctions, 1197 heart failures, 2406 strokes, and 5676 total deaths. Among participants with CKD, compared with those in the lowest tertile of UA, the HRs (95% CIs) of participants in the highest UA tertile were 1.38 (1.13-1.67) for myocardial infarction, 1.60 (1.38-1.85) for heart failure, 1.01 (0.91-1.12) for stroke, and 1.29 (1.21-1.38) for all-cause mortality. Subgroup analyses showed that the associations between UA and heart failure and all-cause mortality were stronger in individuals with estimated glomerular filtration rate <45 mL/min/1.73 m2 compared to their counterparts (Pinteraction < 0.05). Additionally, the association between UA and all-cause mortality was stronger among individuals without diabetes than those with diabetes (Pinteraction < 0.05). Conclusion: In individuals with CKD, a higher concentration of UA was associated with a higher risk of myocardial infarction, heart failure, and all-cause mortality, following a dose-response relationship. Our data underscore the importance of UA screening among individuals with CKD for CVD and premature death prevention.
UR - https://www.scopus.com/pages/publications/85207388454
UR - https://www.scopus.com/inward/citedby.url?scp=85207388454&partnerID=8YFLogxK
U2 - 10.1093/eurjpc/zwae222
DO - 10.1093/eurjpc/zwae222
M3 - Article
C2 - 38946352
AN - SCOPUS:85207388454
SN - 2047-4873
VL - 31
SP - 2058
EP - 2066
JO - European Journal of Preventive Cardiology
JF - European Journal of Preventive Cardiology
IS - 17
ER -